Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This ancillary study enrolls JAK2V617F-positive patients with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis who are high risk for thrombosis and already taking part in the AVAJAK trial. Participants will have blood drawn at baseline and at 12 months to measure NETosis markers such as calprotectin and citrullinated histone H3 (H3Cit). Marker levels will be correlated with subsequent thrombotic events to test whether NETosis biomarkers improve prediction beyond age and prior thrombosis. The goal is to determine whether these measurements can guide safer, more personalized thrombosis prevention strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)
* JAK2V617F mutation with an allelic burden greater than 1%
* High risk of thrombosis (age over 60 years or prior thrombotic event)
* Diagnosis of MPN within the last 12 months
* Enrollment in the AVAJAK clinical trial and the FIMBANK biobank
* Affiliation with social security
* Signed informed consent

Exclusion Criteria:

* Severe hepatic or renal insufficiency (Creatinine clearance \<30ml/min)
* Patients under legal protection (guardianship or curatorship)
* Patients under heparin treatment at inclusion

Where it's running

• CH de Libourne, Service Hématologie
  Libourne, France Recruiting
• CHU d'Angers, Service des maladies du Sang
  Angers, France Not yet recruiting
• CH de la Côte Basque, Service Hématologie
  Bayonne, France Not yet recruiting
• CHU de Bordeaux, Service Hématologie Biologique
  Bordeaux, France Not yet recruiting
• CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
  Bordeaux, France Not yet recruiting
• CHU de Brest, Service Hématologie et Hémostase Clinique
  Brest, France Not yet recruiting

Study contacts

• Principal investigator: Alexandre GUY — alexandre.guy@chu-bordeaux.fr
• Study coordinator: Alexandre GUY
• Email: alexandre.guy@chu-bordeaux.fr
• Phone: 0557656478

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CIML NK cell therapy to prevent relapse after stem cell transplant

  This study is testing if a new type of immune cell therapy can help prevent relapse in people with certain blood cancers after they receive a stem cell transplant.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06138587

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Chemogenomic profiling for blood cancers

  This project will test whether detailed genetic and molecular profiling of bone marrow, blood, or tissue samples can better characterize diagnosis and relapse for people with suspected or known blood cancers.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, PR · NCT07445984

• Multi-omics testing for blood and bone marrow cancers

  This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, PR · NCT07445438

• Comprehensive multi-omics and functional profiling to fully characterize tumors

  This project tests whether detailed multi-omics and functional testing of tumor samples can better characterize high-risk blood and solid cancers for patients at participating centers.

  Recruiting at 2 sites Azienda Ospedaliero-Universitaria di Parma · Palermo, Palermo and 1 other locations · NCT07403630

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.